ANTIBIO

ANTIBIO

ANTIBIOtic therapy after an acute myocardial infarction. A clinical trial that asked whether treatment with a macrolide antibiotic, roxithromycin, would alter the outcomes of acute myocardial infarction. 
Conclusion Roxithromycin changed neither the 1-year mortality nor combined outcomes.
References in periodicals archive ?
The ANTIBIO trial (Antibiotic Therapy for Acute Myocardial Infarction) examined treatment with roxithromycin (a macrolide antibiotic) versus placebo for 6 weeks in 872 patients presenting with acute MI.
ANTIBIO was a double-blind randomized trial of 872 acute MI patients at 68 German hospitals.
Zahn explained that ANTIBIO was a double-blind randomized trial involving 872 acute MI patients at 68 German hospitals.